Your browser doesn't support javascript.
loading
Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
Lam, Marnix G E H; Dahmane, Amel; Stevens, Wil H M; van Rijk, Peter P; de Klerk, John M H; Zonnenberg, Bernard A.
Affiliation
  • Lam MG; Department of Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. M.Lam@umcutrecht.nl
Eur J Nucl Med Mol Imaging ; 35(4): 756-65, 2008 Apr.
Article in En | MEDLINE | ID: mdl-18157530
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organometallic Compounds / Organophosphorus Compounds / Prostatic Neoplasms / Radioisotopes / Samarium / Bone Neoplasms / Diphosphonates / Bone Density Conservation Agents / Imidazoles Type of study: Guideline Limits: Humans / Male Language: En Journal: Eur J Nucl Med Mol Imaging Journal subject: MEDICINA NUCLEAR Year: 2008 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organometallic Compounds / Organophosphorus Compounds / Prostatic Neoplasms / Radioisotopes / Samarium / Bone Neoplasms / Diphosphonates / Bone Density Conservation Agents / Imidazoles Type of study: Guideline Limits: Humans / Male Language: En Journal: Eur J Nucl Med Mol Imaging Journal subject: MEDICINA NUCLEAR Year: 2008 Document type: Article Affiliation country: